Source comparison
Sermorelin Ipamorelin Stack: Research vs Clinical Comparison
Mechanism Stimulates endogenous pulsatile GH secretion via GHRH + ghrelin pathways Exogenous GH administered directly. Bypasses endogenous regulation Ghrelin receptor agonist (orally bioavailable). Single pathway only Peptide stack preserves physiological puls
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates endogenous pulsatile GH secretion via GHRH + ghrelin pathways
- Exogenous GH administered directly. Bypasses endogenous regulation
- Ghrelin receptor agonist (orally bioavailable). Single pathway only
- Peptide stack preserves physiological pulsatility; hGH achieves highest serum levels but suppresses endogenous axis; MK-677 lacks GHRH synergy
- Administration
- Subcutaneous injection nightly before sleep
- Subcutaneous injection daily (dose-dependent)
- Oral capsule daily
- Injection compliance similar for stack vs hGH; oral dosing advantage for MK-677 offset by inferior pulse quality
- IGF-1 Elevation (Typical)
- 30–80 ng/mL above baseline after 8–12 weeks
- 100–200+ ng/mL (dose-dependent)
- 40–60 ng/mL after 12 weeks
- hGH produces highest IGF-1; stack produces moderate sustained elevation; MK-677 plateau occurs at 12–16 weeks
- Receptor Desensitization Risk
- Low (pulsatile signaling matches endogenous patterns)
- N/A (exogenous GH)
- Moderate-high (continuous ghrelin receptor activation)
- Stack's pulsatile design minimizes tachyphylaxis; MK-677's continuous signaling reduces efficacy 20–40% by month 4–6
- Regulatory Status (2026)
- Research-grade peptides from 503B facilities. Not FDA-approved drug products
- FDA-approved prescription medication for specific indications
- Not FDA-approved; sold as research compound
- Stack occupies gray regulatory zone; hGH tightly controlled; MK-677 unregulated but higher safety ambiguity